Crinetics Pharmaceuticals (CRNX) reported a Q4 net loss late Thursday of $0.88 per diluted share, narrowing from the loss of $0.90 a year earlier.
Analysts polled by FactSet expected a loss of $0.89.
No revenue was reported for the quarters that ended Dec. 31 in 2023 and 2024. Analysts surveyed by FactSet projected $700,000 in Q4 2024.
As of Dec. 31, the company had $1.4 billion in cash, cash equivalents and investments, enough to fund the current operating plan into 2029.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.